Biotech Values

[DewDiligence]

More OXGN info from the Wells Fargo conference:

In the Q&A session, one of the analysts (it may have been the host from Wells Fargo) grilled OXGN’s CEO, Fred Driscoll, on the issue of CA4P’s cardiac toxicity. She asked whether cardiac toxicity was the reason Bristol-Myers pulled out of the CA4P collaboration with OXGN in 2001.

Driscoll said No, this was not the reason Bristol pulled out. However, the mere fact that this question about cardiac toxicity was asked shows that this notion continues to be prevalent on the Street.